NHL-2010方案治疗儿童淋巴母细胞淋巴瘤临床疗效及安全性分析

Objective: The aim of this study is to explore the clinical and prognostic feature of childhood lymphoblastic lymphoma (LBL) and to evaluate the efficacy and safety of NHL-2010 protocol. Methods: The clinical data of 20 newly-diagnosed cases of LBL in children from August 2009 to December 2013 in West China Second University Hospital Sichuan Province was retrospectively analyzed. Patients were administrated wtih chemotherapy of NHL-2010 protocol. Kaplan-Meier method was used to estimate the survival time of patients. Results: The median age at diagnosis of children with LBL was 8.8 years (2.3 to 14.3 years). No significant difference was found in the median age at diagnosis between male and female children with LBL (P=0.586). The immunophenotype was T-cell LBL in 12 patients (60.0%) and precursor B-cell LBL in 8 patients (40.0%), respectively. According to St. Jude staging classification, 2 patients (10.0%) were divided into stage I, 1 patients (5.0%) into stage Ⅱ, 12 patients (60.0%) into stage Ⅲ and 5 patients (25%) into stage Ⅳ. 3-year overall survival rates of LBL was 85.0%±8.0%, 2-year event free survival rate was 80.0%±8.9%. 3 cases died, of which 2 cases relapsed and 1 case occurred severe sepsis. Conclusions: The survival rate of LBL patients administrated with NHL-2010 was close to the best level from domestic reports. But, there was a apparent existence of gap between China and International states in the diagnostic and treatment approach, with implementation of further modification of treatment protocols.